Sponsor

Xinjiang Medical University

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Xinjiang Medical University appears in 14 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials14
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

14 shown
Clinical Outcomes of Cardiovascular DiseaseNCT06459934 · lead sponsor · 2024-06-01
RECRUITING
Prognostic Model of HypertensionNCT06160921 · lead sponsor · 2020-01-01
RECRUITING
Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer SurvivorsNCT07622394 · lead sponsor · 2026-09-01
NOT_YET_RECRUITING
Early Aldo Blockade in Subclinical PANCT07727252 · lead sponsor · 2026-08-01
NOT_YET_RECRUITING
Precision Subtyping and Prognostic Study of Heart Failure Based on Multi-Omics Integration and Clinical Indicators: A Prospective Single-Center Cohort StudyNCT07355088 · lead sponsor · 2026-01-01
NOT_YET_RECRUITING
Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection FractionNCT05715697 · lead sponsor · 2023-09-01
UNKNOWN
Metagenomic Analysis of Gut Microbiota in Untreated and Uncontrolled Hypertensive PatientsNCT06284928 · lead sponsor · 2019-12-01
COMPLETED
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast CancerNCT02489409 · lead sponsor · 2015-10-01
UNKNOWN
Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR MutationNCT02001896 · lead sponsor · 2013-12-01
UNKNOWN
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠBNCT02001168 · lead sponsor · 2013-10-01
UNKNOWN
Predicting Heart Failure Outcomes With Biomarkers and ImagingNCT07332520 · lead sponsor · 2012-01-01
COMPLETED
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA SequencingNCT06036563 · collaborator · 2023-09-01
UNKNOWN
Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast CancerNCT01492556 · collaborator · 2011-12-01
UNKNOWN
Effect of Alpha Lipoic Acid on Obesity Related ComorbiditiesNCT00994513 · collaborator · 2009-07-01
COMPLETED

Drugs studied in this sponsor's trials

10 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Xinjiang Medical University as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
cisplatin1
docetaxel1
eplerenone1
erlotinib1
etoposide1
gemcitabine1
Navelbine1
pemetrexed1

Sponsor roles

lead sponsor11
collaborator3
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.